A Torrelo1, A Harto, E Sendagorta
1Department of Dermatology, Hospital Ramón y Cajal, Madrid, Spain.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Recombinant interferon-alpha 2a (rIFN-alpha 2a) showed moderate benefits for severe adult atopic dermatitis (AD). While not affecting IgE levels, it offered therapeutic potential for immune deficiencies in AD patients.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: